{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134184","form_type":"8-K","ticker":null,"cik":"0001577916","company_name":"Premier, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.051173+00:00","generated_at":"2026-06-02T09:59:55.887866+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Premier Q3 FY2024: Revenue $342.6M (+6% YoY), GAAP loss $(0.36)/share due to $140.1M impairment, reaffirms FY outlook","bullets":["Total net revenue $342.6M (+6% YoY); Supply Chain Services $227.7M (+5%), Performance Services $115.0M (+9%).","GAAP net loss $49.2M ($(0.36) diluted EPS) due to $140.1M impairment on Contigo Health business.","Adjusted EPS $0.55, flat YoY; fiscal 2024 guidance reaffirmed.","Executed $400M accelerated share repurchase, expected to fully settle by Q1 fiscal 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134184","json":"https://secwatch.observer/filing/0001193125-24-134184.json","markdown":"https://secwatch.observer/filing/0001193125-24-134184.md","text":"https://secwatch.observer/filing/0001193125-24-134184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1577916/000119312524134184/0001193125-24-134184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1577916/000119312524134184/d827328d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:59:55.887866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1083b6f3fb81bd432f9e8c9d301e0af2d472aa6","claim":"Premier, Inc. reported the fiscal-year 2024 third quarter ended March 31, 2024 results: revenue Total net revenue of $342.6 million, net income GAAP net loss of $49.2 million, or $(0.36) per fully diluted share. Guidance reaffirmed.","evidence_excerpt":"healthcare improvement company, today reported financial results for the fiscal-year 2024 third quarter ended March 31, 2024. Third-quarter results: • Total net revenue of $342.6 million; growth of 6% over the prior-year period • GAAP net loss of $49.2 million, or $(0.36) per fully diluted share, which includes a $140.1 million goodwill, intangible and other","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1577916/000119312524134184/0001193125-24-134184-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal-year 2024 third quarter ended March 31, 2024"},{"label":"Revenue","value":"Total net revenue of $342.6 million"},{"label":"Net income","value":"GAAP net loss of $49.2 million, or $(0.36) per fully diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}